Aquestive Therapeutics, Inc. (AQST)
Oxford Ledge is still expanding full research coverage of AQST. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Aquestive develops pharmaceutical products using proprietary oral film and epinephrine prodrug delivery technologies, manufacturing both licensed and proprietary candidates.
SEC filings
- 8-K Shareholder vote results; Financial statements and exhibits 2026-06-10
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 8-K Entry into material agreement; Termination of material agreement; Results of operations / financial condition; Creation of direct financial obligation; 3.02; Regulation FD disclosure; Financial statements and exhibits 2026-05-13
- DEF 14A Proxy statement for shareholder vote 2026-04-24
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-03-30
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for AQST. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AQST in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.